Arcturus Therapeutics Holdings Inc. (ARCT)
| Market Cap | 1.51B |
| Revenue (ttm) | 10.27M |
| Net Income (ttm) | -52.03M |
| Shares Out | 22.94M |
| EPS (ttm) | -2.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $59.69 |
| Previous Close | $62.27 |
| Change ($) | -2.58 |
| Change (%) | -4.14% |
| Day's Open | 62.34 |
| Day's Range | 59.12 - 65.87 |
| Day's Volume | 1,610,466 |
| 52-Week Range | 9.31 - 123.66 |
Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.
One Wall Street analyst is very bullish about the biotech's prospects.
Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicine...
Over halfway through the trading day on Thursday, and the broad markets are making a run into the afternoon.
The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BiotechShowcase--Arcturus Therapeutics to Present at Upcoming Investor Conference
Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.
This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.
Shares of Arcturus Therapeutics Holdings Inc. gained 3.7% in premarket trading on Monday after the company said the Food and Drug Administration will allow it to move forward with a Phase 2 cl...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.
Investors in fast-moving biotechs made out like bandits.
Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #CFTR--Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
Investors obviously considered these to be underwhelming, however.
Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updat...
The biotech announced disappointing early stage results for its single-dose COVID-19 vaccine candidate.
An update on its COVID-19 vaccine candidate sent Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares were retreating sharply Tuesday after the company issued an update on its coronavirus vaccine program. What Happened: San Diego, Califo...
Investors respond to results from a Phase 1/2 trial of its COVID-19 vaccine candidate that one analyst said were disappointing.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Received Approval from Singapore HSA to Proceed with Phase 2 Study of its Vaccine Candidate & Provides New/Updated Clinical/Precli...
Nothing compares to these companies.
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
They each have a key competitive edge that could set them apart.
The first to market won't necessarily dominate the market over the long run.
Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.
There's something for every kind of investor with this list.
A biotech that no one has heard of has been making a few investors rich for much of 2020.
This could be the perfect time for aggressive investors to scoop up shares.
This can happen when a company holds out its hand for a big chunk of fresh capital.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Pricing of $150.15 Million Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency
Don't be surprised if this small biotech takes off in 2021.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Present at Piper Sandler's 32nd Annual Virtual Healthcare Conference
Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.
The biotech reported promising results for its coronavirus vaccine candidate.
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Quick Version Earnings Call Transcript
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -95.74% and -26.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead f...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 In...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Interim ARCT-021 Phase 1/2 Study Results, and Up to $220 Million in Additional Financial Commitments from S...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
It's still really early for these two biotech stocks. But their experimental COVID-19 vaccines have tremendous potential.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for OTC Deficiency
About ARCT
Arcturus Therapeutics Holdings, an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine trans... [Read more...]
| Industry Biotechnology | Founded 2013 |
| CEO Joseph E. Payne M.Sc. | Employees 88 |
| Stock Exchange NASDAQ | Ticker Symbol ARCT |
Financial Performance
In 2019, ARCT's revenue was $20.79 million, an increase of 31.97% compared to the previous year's $15.75 million. Losses were -$25.99 million, 19.3% more than in 2018.
Analyst Forecasts
According to 12 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is 96.23, which is an increase of 61.22% from the latest price.